Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: quidditch who wrote (712)	11/21/2002 4:33:29 PM
From: keokalani'nui	Read Replies (2) \| Respond to of 3559

Quid As you know, it has been two very good days in a row for BT in general, almost like panic fund buying--regn would be an obvious beneficiary with its early and late clinical line-up. But the breathtaking ascension of REGN is more akin to tmco and alxn, who reported positive clinical findings. MZ once pointed out that the shorts would be getting very nervous now because their theory of axokine dropouts would be evaporating right before their lengthening noses. Add it all up and there you go. Always chance they cured cancer in a P1 patient. vegf-trap 100x more potent than other brand of inhibitor you know! Wildest